InMode (INMD) shares have held steady lately, trading at $16.01 at the last close. Over the past month, the stock has moved up by 9%, reflecting growing interest among investors as they weigh recent performance trends.
While InMode shares have gained nearly 9% over the past month, momentum is just beginning to build after a tough stretch. The current share price of $16.01 leaves the one-year total shareholder return at -13%, reminding investors that the recent uptrend is still set against a much longer-term decline. Signs of renewed interest could hint at shifting sentiment or improving fundamentals, but there is still ground to recover from deeper losses seen over recent years.
If InMode's move has you thinking about other opportunities in the sector, take a moment to see the full range of healthcare stocks in our discovery screener. See the full list for free.
With shares still well off their highs and modest financial growth, investors have to ask whether InMode is undervalued in the current market or if the recent optimism has already priced in the company’s future prospects.
Advertisement
Most Popular Narrative: 1.5% Undervalued
With InMode’s fair value estimated at $16.25, just above the latest close of $16.01, the narrative suggests investors see hidden value even as the market hesitates to follow. This close alignment sets the stage for debate about whether modest growth and sector moves can lift the share price beyond recent sluggishness.
Expansion of direct operations in emerging international markets like Thailand and Argentina, along with a rapidly growing European presence, is expected to drive continued growth in non-U.S. sales. This leverages increasing access to healthcare and higher disposable incomes globally to boost revenue and diversify geographic risk.
Curious how international expansion and bold new product bets could tip the scales? This narrative’s forecast hinges on a few make-or-break financial shifts buried in the projections. If you want to uncover what could send InMode soaring or stalling, dig deeper into these influential assumptions now.
However, persistent regulatory delays or a further drop in consumer demand could quickly undermine the optimism that is driving InMode’s current narrative.
While the consensus price target points to InMode being slightly undervalued, our SWS DCF model sets fair value at $15.71, just below today’s price of $16.01. This suggests the market could be slightly optimistic, especially if long-term declines continue. Does this cast doubt on the recent uptrend, or is it overlooking hidden strengths?
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out InMode for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Build Your Own InMode Narrative
If this perspective does not match yours, or you want to shape your own view based on the full set of data, you can quickly create a personal narrative in just a few minutes. Do it your way
Catch the latest waves in digital innovation by following these 24 AI penny stocks, your ticket to companies at the forefront of artificial intelligence breakthroughs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies
Designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
